Literature DB >> 22001102

Multicenter phase II study of an opioid-based pain control program for head and neck cancer patients receiving chemoradiotherapy.

Sadamoto Zenda1, Kazuto Matsuura, Hiroyuki Tachibana, Akihiro Homma, Tadaaki Kirita, Nobuya Monden, Shigemichi Iwae, Yojiro Ota, Tetsuo Akimoto, Hiroshi Otsuru, Makoto Tahara, Kengo Kato, Masao Asai.   

Abstract

BACKGROUND: The aim of this multi-center phase II study was to clarify the clinical benefit of an opioid-based pain control program for head and neck cancer patients during chemoradiotherapy. PATIENTS AND METHODS: Head and neck cancer patients who were to receive definitive or postoperative chemoradiotherapy were enrolled. The opioid-based pain control program consisted of a three-step ladder, with basic regimens of: The primary endpoint of this study was compliance with radiotherapy.
RESULTS: A total of 101 patients from 10 institutions were registered between February 2008 and May 2009 and included in the analysis. The major combination chemotherapy regimen was cisplatin alone (76%). The rate of completion of radiotherapy was 99% and the rate of unplanned breaks in radiotherapy was 13% (13/101, 90% confidence interval: 9.9-16.5%). Median maximum quantity of morphine used per day was 35 mg (range 0-150 mg).
CONCLUSIONS: Use of a systematic pain control program may improve compliance with CRT.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22001102     DOI: 10.1016/j.radonc.2011.09.016

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  16 in total

1.  Short- and Long-term Opioid Use in Patients with Oral and Oropharynx Cancer.

Authors:  Jessica D McDermott; Megan Eguchi; William A Stokes; Arya Amini; Mohammad Hararah; Ding Ding; Allison Valentine; Cathy J Bradley; Sana D Karam
Journal:  Otolaryngol Head Neck Surg       Date:  2018-11-06       Impact factor: 3.497

2.  A phase II study of HMB/Arg/Gln against oral mucositis induced by chemoradiotherapy for patients with head and neck cancer.

Authors:  Tomoya Yokota; Satoshi Hamauchi; Yukio Yoshida; Takashi Yurikusa; Miho Suzuki; Aiko Yamashita; Hirofumi Ogawa; Tsuyoshi Onoe; Keita Mori; Tetsuro Onitsuka
Journal:  Support Care Cancer       Date:  2018-04-07       Impact factor: 3.603

3.  Chronic Opioid Use Following Surgery for Oral Cavity Cancer.

Authors:  John Pang; Kathryn R Tringale; Viridiana J Tapia; William J Moss; Megan E May; Timothy Furnish; Linda Barnachea; Kevin T Brumund; Assuntina G Sacco; Robert A Weisman; Quyen T Nguyen; Jeffrey P Harris; Charles S Coffey; Joseph A Califano
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2017-12-01       Impact factor: 6.223

4.  Consensus-Based Guidance on Opioid Management in Individuals With Advanced Cancer-Related Pain and Opioid Misuse or Use Disorder.

Authors:  Katie Fitzgerald Jones; Dmitry Khodyakov; Robert Arnold; Hailey Bulls; Emily Dao; Jennifer Kapo; Diane Meier; Judith Paice; Jane Liebschutz; Christine Ritchie; Jessica Merlin
Journal:  JAMA Oncol       Date:  2022-08-01       Impact factor: 33.006

5.  Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with concurrent weekly cisplatin chemoradiotherapy for locally advanced head and neck squamous cell carcinoma.

Authors:  Takatsugu Mizumachi; Akihiro Homma; Tomohiko Kakizaki; Tomohiro Sakashita; Satoshi Kano; Hiromitsu Hatakeyama; Kazuhiko Tsuchiya; Koichi Yasuda; Rikiya Onimaru; Hiroki Shirato; Jun Taguchi; Yasushi Shimizu; Ichiro Kinoshita; Hirotoshi Akita; Satoshi Fukuda
Journal:  Int J Clin Oncol       Date:  2014-07-05       Impact factor: 3.402

6.  Multicenter phase II study of an oral care program for patients with head and neck cancer receiving chemoradiotherapy.

Authors:  Tomoya Yokota; Hiroyuki Tachibana; Tetsuhito Konishi; Takashi Yurikusa; Satoshi Hamauchi; Kensuke Sakai; Masaya Nishikawa; Miho Suzuki; Yayoi Naganawa; Tomoka Hagihara; Hiromi Tsumaki; Tomo Kubo; Maho Sato; Masataka Taguri; Satoshi Morita; Toru Eguchi; Kaoru Kubota; Sadamoto Zenda
Journal:  Support Care Cancer       Date:  2016-02-18       Impact factor: 3.603

7.  Predictors of long-term opioid treatment among patients who receive chemoradiation for head and neck cancer.

Authors:  Jung Hye Kwon; David Hui; Gary Chisholm; Eduardo Bruera
Journal:  Oncologist       Date:  2013-05-30

8.  Prognostic significance of opioid use in the active treatment of advanced colorectal cancer.

Authors:  Yasuhiro Inoue; Takashi Iwata; Yoshinaga Okugawa; Aya Kawamoto; Junichiro Hiro; Yuji Toiyama; Koji Tanaka; Keiichi Uchida; Yasuhiko Mohri; Masato Kusunoki
Journal:  Mol Clin Oncol       Date:  2012-08-31

9.  Establishment of a research policy for supportive and palliative care in Japan.

Authors:  Sadamoto Zenda; Yosuke Uchitomi; Tatsuya Morita; Takuhiro Yamaguchi; Akira Inoue
Journal:  Jpn J Clin Oncol       Date:  2021-04-01       Impact factor: 3.019

10.  Objective evaluation of nutritional status using the prognostic nutritional index during and after chemoradiotherapy in Japanese patients with head and neck cancer: a retrospective study.

Authors:  Daichiro Fujiwara; Masanobu Tsubaki; Tomoya Takeda; Makoto Miura; Shozo Nishida; Katsuhiko Sakaguchi
Journal:  Eur J Hosp Pharm       Date:  2019-08-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.